Literature DB >> 20538168

Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome.

Marta Tomás1, Carlo Napolitano, Luciana De Giuli, Raffaella Bloise, Isaac Subirana, Alberto Malovini, Riccardo Bellazzi, Dan E Arking, Eduardo Marban, Aravinda Chakravarti, Peter M Spooner, Silvia G Priori.   

Abstract

OBJECTIVES: We investigated the role of nitric oxide 1 adaptor protein (NOS1AP) as a genetic modifier of long QT syndrome (LQTS).
BACKGROUND: LQTS risk stratification is complicated by the phenotype variability that limits prediction of life-threatening arrhythmic events based on available metrics. Thus, the identification of new markers is desirable. Recent studies have shown that NOS1AP variations in the gene modulate QT interval in healthy and 1 LQTS kindred, and occurrence of cardiac events in healthy subjects.
METHODS: The study included 901 patients enrolled in a prospective LQTS registry. Three NOS1AP marker SNPs (rs4657139, rs16847548, and rs10494366) were genotyped to assess the effect of variant alleles on QTc and on the incidence of cardiac events. We quantified the association between variant alleles, QTc, and outcomes to assess whether NOS1AP is a useful risk stratifier in LQTS.
RESULTS: Variant alleles tagged by SNPs rs4657139 and rs16847548 were associated with an average QTc prolongation of 7 and 8 ms, respectively (p < 0.05; p < 0.01); whereas rs4657139 and rs10494366 were associated with increased incidence of cardiac events (25.2% vs. 18.0%, p < 0.05 and 24.8% vs. 17.8% p < 0.05). Cox multivariate analysis identified rs10494366 minor allele as an independent prognostic marker among patients with QTc <500 ms (hazard ratio: 1.63; 95% confidence interval: 1.06 to 2.5; p < 0.05) but not in the entire cohort.
CONCLUSIONS: Our results provide the first demonstration, to our knowledge, of a risk-conferring genetic modifier in a large LQTS cohort. Subject to confirmation in additional cohorts, we suggest that the NOS1AP tag SNP genotype may provide an additional clinical dimension, which helps assess risk and choice of therapeutic strategies in LQTS. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538168     DOI: 10.1016/j.jacc.2009.12.065

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  73 in total

1.  Common genetic variants, QT interval, and sudden cardiac death in a Finnish population-based study.

Authors:  Peter A Noseworthy; Aki S Havulinna; Kimmo Porthan; Annukka M Lahtinen; Antti Jula; Pekka J Karhunen; Markus Perola; Lasse Oikarinen; Kimmo K Kontula; Veikko Salomaa; Christopher Newton-Cheh
Journal:  Circ Cardiovasc Genet       Date:  2011-04-21

2.  Epidemiology and genetics of sudden cardiac death.

Authors:  Rajat Deo; Christine M Albert
Journal:  Circulation       Date:  2012-01-31       Impact factor: 29.690

Review 3.  Genetic testing for inherited cardiac disease.

Authors:  Arthur A M Wilde; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

Review 4.  Genotype- and phenotype-guided management of congenital long QT syndrome.

Authors:  John R Giudicessi; Michael J Ackerman
Journal:  Curr Probl Cardiol       Date:  2013-10       Impact factor: 5.200

5.  An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval.

Authors:  Ashish Kapoor; Rajesh B Sekar; Nancy F Hansen; Karen Fox-Talbot; Michael Morley; Vasyl Pihur; Sumantra Chatterjee; Jeffrey Brandimarto; Christine S Moravec; Sara L Pulit; Arne Pfeufer; Jim Mullikin; Mark Ross; Eric D Green; David Bentley; Christopher Newton-Cheh; Eric Boerwinkle; Gordon F Tomaselli; Thomas P Cappola; Dan E Arking; Marc K Halushka; Aravinda Chakravarti
Journal:  Am J Hum Genet       Date:  2014-05-22       Impact factor: 11.025

6.  Long QT syndrome type 5-Lite: Defining the clinical phenotype associated with the potentially proarrhythmic p.Asp85Asn-KCNE1 common genetic variant.

Authors:  Conor M Lane; John R Giudicessi; Dan Ye; David J Tester; Ram K Rohatgi; J Martijn Bos; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2018-04-03       Impact factor: 6.343

7.  Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.

Authors:  David G Strauss; Jose Vicente; Lars Johannesen; Ksenia Blinova; Jay W Mason; Peter Weeke; Elijah R Behr; Dan M Roden; Ray Woosley; Gulum Kosova; Michael A Rosenberg; Christopher Newton-Cheh
Journal:  Circulation       Date:  2017-02-17       Impact factor: 29.690

8.  R engine cell: integrating R into the i2b2 software infrastructure.

Authors:  Daniele Segagni; Fulvia Ferrazzi; Cristiana Larizza; Valentina Tibollo; Carlo Napolitano; Silvia G Priori; Riccardo Bellazzi
Journal:  J Am Med Inform Assoc       Date:  2011-01-24       Impact factor: 4.497

Review 9.  Genetics of sudden cardiac death caused by ventricular arrhythmias.

Authors:  Roos F Marsman; Hanno L Tan; Connie R Bezzina
Journal:  Nat Rev Cardiol       Date:  2013-12-10       Impact factor: 32.419

10.  Genetic Basis of Ventricular Arrhythmias.

Authors:  Raha Pazoki; Arthur A M Wilde; Connie R Bezzina
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.